JP2023540799A - 多重特異性免疫標的化分子及びその使用 - Google Patents

多重特異性免疫標的化分子及びその使用 Download PDF

Info

Publication number
JP2023540799A
JP2023540799A JP2023516074A JP2023516074A JP2023540799A JP 2023540799 A JP2023540799 A JP 2023540799A JP 2023516074 A JP2023516074 A JP 2023516074A JP 2023516074 A JP2023516074 A JP 2023516074A JP 2023540799 A JP2023540799 A JP 2023540799A
Authority
JP
Japan
Prior art keywords
amino acid
cdr2
cdr1
cdr3
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023516074A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540799A5 (https=
Inventor
ガネサン，ラジクマール
ハンセン，マイケル，リース
グレワル，イクバル，エス．
シング，サンジャヤ
Original Assignee
ヤンセン バイオテツク，インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク，インコーポレーテツド filed Critical ヤンセン バイオテツク，インコーポレーテツド
Publication of JP2023540799A publication Critical patent/JP2023540799A/ja
Publication of JP2023540799A5 publication Critical patent/JP2023540799A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023516074A 2020-09-11 2021-09-10 多重特異性免疫標的化分子及びその使用 Pending JP2023540799A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063077407P 2020-09-11 2020-09-11
US202063077458P 2020-09-11 2020-09-11
US202063077415P 2020-09-11 2020-09-11
US63/077,415 2020-09-11
US63/077,407 2020-09-11
US63/077,458 2020-09-11
US202163165050P 2021-03-23 2021-03-23
US63/165,050 2021-03-23
PCT/US2021/049769 WO2022056199A1 (en) 2020-09-11 2021-09-10 Multi-specific immune targeting molecules and uses thereof

Publications (2)

Publication Number Publication Date
JP2023540799A true JP2023540799A (ja) 2023-09-26
JP2023540799A5 JP2023540799A5 (https=) 2024-09-19

Family

ID=80629898

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023516074A Pending JP2023540799A (ja) 2020-09-11 2021-09-10 多重特異性免疫標的化分子及びその使用

Country Status (11)

Country Link
US (2) US20220089737A1 (https=)
EP (1) EP4211172A4 (https=)
JP (1) JP2023540799A (https=)
KR (1) KR20230084507A (https=)
AU (1) AU2021338776A1 (https=)
CA (1) CA3194752A1 (https=)
IL (1) IL301242A (https=)
MX (1) MX2023002945A (https=)
TW (1) TW202227494A (https=)
UY (1) UY39416A (https=)
WO (1) WO2022056199A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10287346B2 (en) * 2015-04-28 2019-05-14 Mitsubishi Tanabe Pharma Corporation RGMa binding protein and use thereof
MX2021010857A (es) 2019-03-11 2021-12-15 Janssen Biotech Inc Anticuerpos biespecificos anti-v(beta17)/anti-cd123.
CA3192204A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
WO2022056197A1 (en) * 2020-09-11 2022-03-17 Janssen Biotech, Inc. Immune targeting molecules and uses thereof
TW202227495A (zh) 2020-09-11 2022-07-16 美商健生生物科技公司 用於調節β鏈介導之免疫的方法及組成物
JP2024507180A (ja) * 2021-02-16 2024-02-16 ヤンセン ファーマシューティカ エヌ．ベー． Ｂｃｍａ、ｇｐｒｃ５ｄ、及びｃｄ３を標的とする三重特異的抗体
US12365743B2 (en) 2022-02-23 2025-07-22 Xencor, Inc. Anti-CD28 x anti-PSMA antibodies
CN119255825A (zh) * 2022-05-24 2025-01-03 第一三共株式会社 抗-cdh6抗体-药物缀合物的剂量方案
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024040220A2 (en) * 2022-08-19 2024-02-22 Regents Of The University Of Minnesota Cd83 binding fusion proteins
WO2024040228A2 (en) * 2022-08-19 2024-02-22 Regents Of The University Of Minnesota Cd83 binding proteins
EP4662239A1 (en) * 2023-02-09 2025-12-17 Janssen Biotech, Inc. Anti-v beta 17/anti-cd123 bispecific antibodies
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
CN117187180B (zh) * 2023-11-03 2024-01-26 四川大学 一种Th17细胞及其培养方法和应用及其诱导液
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160347858A1 (en) * 2015-04-16 2016-12-01 Eisai R&D Management Co., Ltd. Anti Human Notch4 Antibody
US20170015738A1 (en) * 2015-07-13 2017-01-19 H. Lundbeck A/S Antibodies Specific for Hyperphosphorylated Tau and Methods of Use Thereof
WO2019091384A1 (en) * 2017-11-08 2019-05-16 Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. Conjugates of biomolecule and use thereof
WO2020010250A2 (en) * 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2020142672A2 (en) * 2019-01-04 2020-07-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1877075A4 (en) * 2005-04-25 2008-07-30 Pfizer ANTIBODY TO MYOSTATIN
US9315577B2 (en) * 2008-05-01 2016-04-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US9790274B2 (en) * 2013-03-14 2017-10-17 The Board Of Regents Of The University Of Texas System Monoclonal antibodies targeting EpCAM for detection of prostate cancer lymph node metastases
SG10201913782UA (en) * 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cll-1 chimeric antigen receptor
US10800843B2 (en) * 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
EP3356415B1 (en) * 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
US11370830B2 (en) * 2017-04-07 2022-06-28 The Rockefeller University Neutralizing antibodies that bind to the zika virus domain III envelope region
MX2020014243A (es) * 2018-06-19 2021-05-12 Biontech Us Inc Neoantigenos y usos de los mismos.
MX2021010857A (es) * 2019-03-11 2021-12-15 Janssen Biotech Inc Anticuerpos biespecificos anti-v(beta17)/anti-cd123.
EP3986936A4 (en) * 2019-06-21 2023-03-15 Single Cell Technology, Inc. ANTI-TIGIT ANTIBODIES
AU2020359070A1 (en) * 2019-10-03 2022-04-21 Janssen Biotech, Inc. Methods for producing biotherapeutics with increased stability by sequence optimization
AU2021225870A1 (en) * 2020-02-27 2022-10-20 Janssen Biotech, Inc. Materials and methods for modulating an immune response

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160347858A1 (en) * 2015-04-16 2016-12-01 Eisai R&D Management Co., Ltd. Anti Human Notch4 Antibody
US20170015738A1 (en) * 2015-07-13 2017-01-19 H. Lundbeck A/S Antibodies Specific for Hyperphosphorylated Tau and Methods of Use Thereof
WO2019091384A1 (en) * 2017-11-08 2019-05-16 Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. Conjugates of biomolecule and use thereof
WO2020010250A2 (en) * 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2020142672A2 (en) * 2019-01-04 2020-07-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof

Also Published As

Publication number Publication date
AU2021338776A9 (en) 2024-06-13
UY39416A (es) 2022-03-31
CA3194752A1 (en) 2022-03-17
KR20230084507A (ko) 2023-06-13
TW202227494A (zh) 2022-07-16
MX2023002945A (es) 2023-06-12
EP4211172A4 (en) 2024-10-09
EP4211172A1 (en) 2023-07-19
IL301242A (en) 2023-05-01
WO2022056199A1 (en) 2022-03-17
US20250043004A1 (en) 2025-02-06
AU2021338776A1 (en) 2023-05-25
US20220089737A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
US20250043004A1 (en) Multi-specific immune targeting molecules and uses thereof
US12492256B2 (en) Methods and compositions for modulating beta chain mediated immunity
WO2020227457A1 (en) Materials and methods for modulating t cell mediated immunity
US20260055185A1 (en) Materials and methods for modulating delta chain mediated immunity
US12448449B2 (en) Immune targeting molecules and uses thereof
WO2022216887A1 (en) Novel anti-cd4 antibodies
CN116615456A (zh) 用于调节β链介导的免疫的方法和组合物
CN116490519A (zh) 多特异性免疫靶向分子及其用途
BR122024018564A2 (pt) Anticorpo multiespecífico e seu uso, composição farmacêutica, seu método de produção e seu uso, ácido nucleico, vetor, célula hospedeira, e kit
HK40099157A (zh) 用於调节β链介导的免疫的方法和组合物
WO2026035888A1 (en) Methods and compositions for modulating beta chain mediated immunity
JP2024543019A (ja) β鎖媒介免疫を調節するための組成物及び方法

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240910

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260413